From: Development and clinical validation of CT-based regional modified Centiloid method for amyloid PET
 | Head-to-head cohort | Clinical validation cohort | ||
---|---|---|---|---|
FMM | FBB | p-value | ||
N | 63 | 1203 | 1042 | Â |
Age (years) | 58.7±19.4 | 69.7±9.8 | 69.4±10.8 | 0.63 |
Gender (F), N (%) | 37 (58.7) | 671 (55.8) | 589 (56.5) | 0.72 |
APOE4 carriers, N (%) | 25 (39.7) | 417 (35.4) | 426 (42.7) | 0.001 |
SVLT delayed recall, mean ± SD | 3.2±3.4 | 3.3±3.2 | 2.7±3.1 | <0.001 |
MMSE, mean ± SD | 26.6±5.5 | 24.9±4.9 | 24±5.5 | <0.001 |
CDR-SOB, mean ± SD | 3.4±3.9 | 2.4±2.8 | 3.2±3.3 | <0.001 |
NC/aMCI/ADD, N | 38/0/25 | 346/554/303 | 281/379/382 | Â |